VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotechnology company developing second generation psychedelics for neuro-psychiatric disorders, today announced that Dr. Thomas Laughren will join BetterLife as a Regulatory Advisor. Dr. Laughren was formerly Director for the…


Previous articleMINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
Next articlePTSF54 – Theft, Patents, and Ethical Psychedelic Companies